Event update - Hansa Biopharma
We hosted a Deep Dive Event yesterday with Elisabeth Sonesson - Global Franchise Lead Autoimmune Diseases.
Learn more about this interesting rare disease company.
Elisabeth Sonesson deep dive into other indications for Imlifidase. Like Anti GBM, GBS and AMR. Why do Hansa expect Imlifidase to be better than the current plasma replacement therapy and are the regulatory bodies EMA/FDA ready to handle these new types of treatment. These and many other questions will Elisabeth Sonesson answer during her presentation.
Watch the interview here: https://www.inderes.dk/videos/hansa-biopharma-deep-dive-into-other-indications-for-imlifidase
Disclaimer:
HC Andersen Capital receives payment from Hansa Biopharma for a Digital IR/Corporate Visibility subscription agreement. /ANALYST Claus Thestrup 07:10 AM 05-31-2023.
Hansa Biopharma
Hansa Biopharma is a Swedish biotech company with the lead product imlifidase, which is an antibody-cleaving enzyme being developed to enable kidney transplantation in highly sensitized patients. The enzyme may be further developed for use in other types of transplantation, in autoimmune diseases, gene therapy and oncology. So far Idefirix (imlifidase) has been conditionally approved in the EU for highly sensitized kidney transplant patients. Currently, Hansa is conducting a pivotal randomized contro trial in kidney transplantation in the United States and is expecting to commence a pivotal study across the U.S. and EU in the rare autoimmune disease anti-GBM during 2022. Additionally, Hansa’s research and development program is advancing the enzyme technology to develop the next generation of IgG-cleaving enzymes with potentially lower immunogenicity, suitable for repeat dosing in relapsing autoimmune diseases and oncology.
Read more on company page